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Summary G1147211 is a novel. totally synthetic camptothecin with promising preclinical and early clinical activity. This study was designed to
determine the maximum tolerated dose of Gl147211 as a 72-h infusion and to describe its pharmacokinetics and pharmacodynamics on this
schedule. In a single-arm, rising-dose study in patients with advanced cancer, eight cohorts of three or more patients received 72-h infusions
of G1147211 at doses ranging from 0.25 to 2.5 mg m-2 day-'. Forty-four patients received a total of 124 cycles. All patients had refractory
tumours and 40 had received prior chemotherapy and/or radiotherapy. Whole-blood G1147211 lactone, total blood and total concentrations
were measured during and over the 12 h following the infusion. Myelosuppression was observed at all dose levels. Neutropenia was dose
limiting at 2.0 mg m-2 day-' in minimally pretreated patients, while both neutropenia and thrombocytopenia were limiting at 1.5 mg m-2 day-' in
those more heavily pretreated. Phlebitis occurred with infusions through peripheral veins early in this study, necessitating the use of central
venous access. Other toxicities included mild nausea and vomiting, fatigue, headache, central venous catheter infections and alopecia. Three
partial and two minor responses lasting 8-34+ weeks were noted in patients with ovarian, colon and breast carcinomas and hepatoma. Mean
steady-state concentrations of G1147211 increased with dose over a range of 0.25-1.24 ng ml'. The mean terminal elimination hatf-life was
7.5 h. and the clearance averaged 1074 ml min-' m-2 over the doses studied. The mean fractional excretion of unchanged drug in urine was
0.114. Gi147211 lactone exposure correlated with haematological toxicity. The recommended phase II doses forthis regimen are 1.75 mg m-2
day-' and 1.2 mg m-2 day-' for minimally pretreated and heavily pretreated patients respectively. At these doses, steady-state G1147211
concentrations within the range of those effective in vitro were achieved. Extensive phase 11 evaluation of this compound and further phase
trials evaluating more prolonged infusions are ongoing.
Keywords: G1147211: GG211: camptothecin analogues: topoisomerase inhibitor; phase trial; pharmacokinetics: pharmacodynamics:
continuous infusion
GI147211 (7-4 methyl piperazinomethilene)-10.11-ethylenedioxy-
20-(S camptothecin: Figure 1) is a totally synthetic analogue of
camptothecin. a natural product isolated from Camptotheca
acuminata (WAall et al. 1966: Emerson et al. 1995). Despite the
sicrnificant anti-tumour actixvity of the parent compound camp-
tothecin in preclinical models and in early clinical trials. its further
development >-as compromised by severe and unpredictable toxi-
citv involxino the bone marrow. gastrointestinal tract and urothe-
lium (Gottlieb et al. 1970: Mluggia et al. 1972). In part. the
insolubility of camptothecin x-as central to this undesirable
adxerse picture. The nuclear enzyvme DNA topoisomerase I. x hich
relaxes DNA supercoils arising during, replication and gene tran-
scription. has been identified as the specific targret ofcamptothecin
(Hsianer and Liu. 1988: Wall and Wani. 1995). The mechanism of
cytotoxicity of camptothecin (and of its analogues) involves the
formation of a coxalent complex Awith topoisomerase I and DNA:
this cleavable complex stabilizes DNA single strand break-s. xwhich
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mav be converted to double strand break-s upon encountering a
replication fork (Zhang et al. 1990: Slichenmver et al. 1993).
Topoisomerase I enzN-me lexels in cancer cell lines and in surmical
specimens of a range of human tumours are higher than those of
normal tissues (Giovanella et al. 1989: Husain et al. 1994). These
findings stimulated the clinical evaluation of less toxic. water-
soluble analogues of camptothecin. The semisynthetic derivatives
topotecan and irinotecan (CPT-l1b has-e rood preclinical anti-
tumour activitx. reproducible toxicitv in earlx clinical trials and
encouraging activitv in several human tumours (Slichenmver et al.
1993; Potmesil. 1994: Wall and W'ani. 1995).
GI14721 1 is a whollv synthetic camptothecin analogue in w-hich
molecular modifications have been made to enhance w-ater solu-
bilitv and to increase affinity for topoisomerase I. As w-ith all
camptothecin analogues. GI14721 1 exists in a pH-dependent equi-
librium betwxeen the lactone (the active forr) and the open-ring
carboxvlate. In xitro. G1147211 has demonstrated substantial
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actixvity against a broad range of cell lines. In vixo studies usinr,
colon (HT29 and SW480). breast (MX1). oxarian (SKOV3).
prostate (PC3) and lung (H460) carcinoma xenografts in nude
mice confirmed the anti-tumour actixitv (Emerson et al. 1986.
1993. 1994. 1995). In preclinical models. topoisomerase I
inhibitors demonstrate greater in vitro and in vivo anti-tumour
activity when administered by repeat doses or by prolonged infu-
sion. To exploit this apparent schedule dependency. we initiated a
phase I trial ofGI147211 by 72-h infusion.
PATIENTS AND METHODS
Patient selection
This phase I study was conducted as an international collaboratix e
trial betuxeen Fox Chase Cancer Center and the Cancer Research
Campaign (CRC) Department of Medical Oncology at the
Universitv of Glasgow. Elicible patients had histologically docu-
mented solid tumours which were considered to be refractory to
consentional therapv. They were over 18 years of age. with an
Eastern Cooperative Oncologv Group (ECOG) performance status
of 0-2. They had adequate bone marrow (WBC count >4000 l1j.
g5ranulocyte >2000 gl-' and platelet count >100 000 l1il ) lixer
[bilirubin level <1.5 mg dl-I and aspartate aminotransferase (AST)
.4x upper normal value] and kidney (serum creatinine concentra-
tion <1.5 ma dl-I or creatinine clearance .60 ml min-' ) function.
Patients were required to have recovered from all toxicities of
prior treatment and to have received no cytotoxic chemotherapy
within the previous 3 weeks (6 weeks in the case ofnitrosoureas or
mitomvcin C). All patients rasve written informed consent. During
the course of this study. placement of a central vein catheter A-as
made a requirement.
Before therapy a medical history. physical examination.
complete blood count. biochemical profile. urinalysis. electrocar-
dioggraphy and chest radiography were performed. Patients were
monitored with weekly blood counts and biochemical profiles. and
clinical examinations were performed on exerv course. Doses
were not escalated wxithin patients. Results are reported using the
Common Toxicits Criteria (Cancer Therapy Ev-aluation Program.
National Cancer Institute. Bethesda. MD. 1988). Patients with
measurable disease were evaluated (usually by radiographic scan
or X-rav) every other course: those with stable disease or better
Table 1 Characteristcs of treated patients
Patients. number
Median age, years (range)
Men/Women
Performance status
0
1
Primary tumour
Colorectal
Ovanan
Renal
Sarcoma
Breast
Pancreas
Head and neck
Others
Pnor treatment
None
Chemotherapy alone
Chemotherapy + radiotherapy
x ere continued on therapy.
(Miller et al. 1981 ).
44
60 (22-79)
22/22
21
22
1
23
5
3
1
2
2
2
6
4
26
14
Response criteria x ere standard
Drug administration
Initial stability studies rexealed that GI14721 1 xAas stable either as
a concentrate or as a more dilute solution in 5%7 dextrose (axvera-e
pH 5). A uniform preparation of5%7 dextrose USP was proxided as
the sole acceptable diluent for this trial. Afterdilution in 96 ml. the
drucg was administered as a continuous infusion using an ambula-
tory infusion pump. Medication bags and extension tubingr were
changed evers day during therapy and x ere protected from light at
all times. Aliquots of the administered solution were obtained to
confirm the stabilitv ofGI14721 1.
Significant interspecies differences in toxicity prompted selec-
tion of a starting dose of G1147211 of 0.25 mc m- day- . which
xxas less than 1/30 the munrneLD,I,. GI14721 1 was administered as
a 72-h infusion: courses xxere repeated every 4 wxeeks. provided
Table 2 Haematological toxicity expressed in CTC grades as the worst expenenced per patient
Dose n Leucopenia Neutopenia Thrombocytopenia Anaemia
(mg rn-2 day-')
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
0.25 6 - - - - - - - - 1 - - - 2 - - -
0.50 4 1 - - - - - - - - - - - 1 - - -
1.0 5 - 1 1 - 1 - - - 1 - - 1 - - 1 -
Minimal pretreatment
1.5 5 - 2 - 1 - - 2 1 1 1 1 1 - 2 2 -
1.75 3 - - 1 - - - 1 - - - - - 1 - 1 -
2.0 10 4 1 1 2 2 2 - 3 2 1 4 - 4 4 1 -
2.5 2 - - 1 1 - - - 2 - - 1 1 - - 1 -
Heavy pretreatment
1.2 3 1 1 - - 1 - - - 2 - 1 - 1 2 - -
1.5 4 - - 2 1 - - - 3 - - - 3 1 2 - -
2.0 1 - - - 1 - - - 1 - - - 1 - - 1 -
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Gil147211 pharnmacokinetics
Pharmnacokinetic sampling
Blood and urine samples for the deterrmination of GI1147211 phar-
macokinetics w~ere obtained durngn the first cycle. Blood samples
(7 ml) wAere collected in heparinized tubes before infusion and at 2.
4. 6. 8. 14. 26. 32. 38. 50. 56. 62 and 72 h after startincn the infu-
sion. and at 15. 25 and 45 min. and 1. 1.5. 2.4. 6. 8. 10 and 12 h
after the infusion had been completed. Urine wxas collected durngnc
treatment and in timed samples for 24 h after treatment. Whole-
blood samples wxere placed in ice-wxater immediately after collec-
tion. frozen xsithin 30 min and kept at -20'C until analyIsis.
Analyticalprocedure
A GLP-v-alidated HPLC assav A-as used for all GI1147211 measure-
ments (Stafford and St Clairfe. 1995). 61147211 is extracted from
cold blood by a mixture of 1:4 (vIv) acetonitrile and butylchloride.
Samples are kept in an ice slurry bath before extraction as the
conversion of lactone to carboxyvlate is slowsed down dramatically
by the low temperatures of the ice slumn. The orgai phase is
collected and evaporated dowsn under a stream of nitrogen. The
reidue is reconstituted vNith a 1:4 (v/v) solution of acetronitrile
and sodium phosphate buffer (pH 4). This solution is inj'ected onto
an HPLC system equipped wsith a BDS Hyperfil C~column
(250 mm x 4.6 mm) and fluorescence detector. The range of the
assay is 0.15-100 ng, ml' with sufficient precision and accuracv
(coeffecient of variation <10%7). The mobile phase consists of
25%7 acetonitrile and 10% ammonium acetate buffer pumped at
1.7 ml rmm'n. The internal standard used in this assav is 6.7-
dimethoxy-4-methylcoumnarin (Stafford and St Claire. 1995).
Pharmacokinetic analysis
Plasma G11472 11 concentration vs time curves wxere evaluated
using model-independent methods (Gibaldi. 1984). The averagte
steady-state concentration (C A was determined by taking h
average concentration after steadyv-state wxas achieved. Syvstermic
blood clearance (CL) wxas estimated using, the equation:
CL=K/C_
A-here K, is the infusion rate. The terrminal rate constant Xz xxas
determined by linear regression of log, transformation of the blood
concentration vs time curse followsing the end of the infusion. The
terminal half-life (t, 41 wxas calculated by the equation:
til =0.693fA~.
Sigma Plot (release 2.0. Jandel Scientific. San Rafael. CA. USA)
wxas used to generate plots and perform linear regression of C xvs
Table 3 Non-haematological toxict expressed in CTC grades as the worst experienced per patient
Dose n Nausea Vomiting Diarrhoea Anorexia Fatigue Mucositis Akopecia Headache
(mng M-2day-)
1 2 34 1 23 4 1 23 4 1 2 34 12 34 1 2 34 12 34 1 23 4
0.25 6 3 ..-- -- 1 2 ..-- -- 1
0.50 4 1 21 -2 1-- 1 1 2 .... -2 -- -
1.0 5 3 1-- 3--- 1 2--- 4 ..-- --1 3 -- -
1.2 3 - 1 1 1....--- 1 -1
1.5 10 4 3 - - 3 2.-- - - - - 5 1 - - 2 4 - - 2 - - - 6 1 - - 3 - - -
1.75 3 2 ..- - - - 1.... 1
2.0 11 4 11 -1 21 -2 -1 -2 1-- 4 2-- 1 4 2 .---
2.5 2 1 ..-- --1 1 1 1 -1.-----
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Table 4 Pharmacokinetic parameters of GI147211 (lactone) following 72-h
continuous infusion
Dose CSS Half-life Clearance
(mg m-2 day-') n (ng mi-1) (h) (ml min-1 m-2)
Mean ± s.d. Mean ± s.d. Mean * s.d.
%CV %CV %CV
0.25 6 0.25 : 0.10 ND- 776 t 276
39 36
0.5 4 0.440.14 ND- 864 -333
33 39
1.0 5 0.86-0.15 7.9a-1.4 826 139
17 18 17
1.2 3 0.74
- 0.30 6.1: 1279 : 559
41 - 44
1.5 10 1.09 :0.34 7.4 4.3 1046 : 315
31 58 30
1.75 3 1.10 : 0.23 8.9c + 1.2 1138 + 259
21 13 23
2.0 11 1.09 -0.24 7.2c + 3.0 1290 ± 246
22 42 19
2.5 2 1.21 0.55 8.5+4.9 1554+691
44 58 44
Overall mean 7.5 1074
s.d. 3.2 0.363
%CV 43 34
n 29 44
ND = not done: insufficient measurable concentrations. an =4. :n = 1. cn
-n= 10.
dose. Biopak (release 2.0 Portland. OR. USA) was used to esti-
mate Az. PCNONLIN (release 4.0. Apex. NC. USA) w-as used to fit
the pharmacokinetic and pharmacodynamic data to a sigmoidEr
(Hill) equation ofthe following form:
%e decrease in neutrophils or platelets = l _
(CSS! + EC4;4)
RESULTS
The demographic characteristics of patients treated in this studv
are presented in Table 1. Forty-four patients receir ed 124 courses
ofGI14721 1. The median number ofcourses per patient was three
(range 1-8). A majority of patients had colorectal cancer and the
mean performance status was excellent.
Haematological toxicity
Eight dose lev-els ranging from 0.25 to 2.5 m m- dayv- were
studied. Myvelosuppression was obser-ed at all dose levels and w-as
dose dependent and non-cumulative (Table 2). Only grade I or II
haematological toxicity was noted at doses of 1.0 mg m-' day-'.
with the exception of a single patient who had previously experi-
enced severe myelotoxicitv followina treatment with carboplatin
and taxotere. At doses > 1.5 mg, m-' dav-l. 'grade IV myelosuppres-
sion was observed and criteria for dose-limiting toxicitv fulfilled.
The severity of mvelosuppression seemed to be related to the
extent of prior therapy: accordingly. a representative sample of
both heavilyv and minimally pretreated patients was accrued as
stipulated previously.
Patients who were heavily pretreated experienced more myelo-
suppression at a gixen dose level (Table 2). Four of ten patients
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Figure 2 Relationship between dose and lactone Css (patient average
value)
treated at 1.5 mg m- day-' were heavily pretreated: three devel-
oped grade IV thrombocytopenia along Awith grade Ill or IV
neutropema. Two of these patients developed neutropenic fever in
the first cycle. As three patients had DLT episodes. the next dose
level selected for heavily pretreated patients was 1.2 mu m-' day-l
Three patients were treated at this dose level without significant
bone marrow toxicity. However. before the effect of pre%-ious
treatment on haematological toxicity became apparent. one
heavily pretreated patient was included at 2.0 mcu m-' dav-': he
developed grade IV neutropenia and thrombocytopenia.
Therefore. in heavily pretreated patients. the MTD w-as 1.2 mg m-
day"'. At this dose. onlv minimal neutropenia was observed.
Platelet nadirs appeared 18 days after the beginning ofthe infusion
(ranae 15-22) with a median count of 75 x 1091-1 (ranae 31-93).
In contrast to the heavily pretreated patients. two of six mini-
mally pretreated patients entered at 1.5 mg mr2 dav-y had transient
rade HI and one grade IV neutropenia. Two patients experienced
grade III or worse thrombocytopenia. but no episodes ofDLT vere
recorded. At 1.75 mcg m-' dayv-. onlyv one of the three patients
experienced grade III neutropenia. Among, ten minimally
pretreated patients studied at 2.0 mg, m-' day-'. four experienced
grade HIIIIV myelosuppression. only one of Ahom met the criteria
of DLT. Two additional patients were studied at 2.5 ma m- dav
and both developed dose-limiting neutropenia durina the first
course. The MTD for minimally pretreated patients A-as 2.0 mc
m- day-l. At this dose level. the lowest nadir neutrophil count per
patient occurred at a median of 16.5 days (ranae 10-22) after the
initiation of the infusion with a median value of 1.59 x 109 1-
(range 0.02-3.92). The platelet nadir occurred at day 15 (range
8-20) and had a medianvalue of72 x 1091-1 (range 7-219).
Grade II or III anaemia occurred in 15 of 29 patients treated at
doses > 1.2 mc m-' dav-'. Nine patients received 13 transfusions of
24 packs of red cells. 67%7 of them during the first cycle. The
median duration of grade III or IV thrombocytopenia was 4 days
(range 1-10 days) and five patients required transfusions of
platelets (range 1-3). Five of the ten patients A-ith grade IV
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Figure 3 Relationship between dose and lactone clearance. An increase in
clearance is shown at doses > 1 mg m-2 day-,
neutropenia episodes (median duration 5 days. range 1-14) devel-
oped fever and two had microbiologically documented infections.
Non-haematological toxicity
Twenty-six patients experienced grade I or II nausea and 16 had
arade I or II vomiting (Table 3). Three patients had grade III
vomiting. Fifteen of these patients had nausea and/or vomiting
before starting, the infusion of GI147211. Emesis was not dose
dependent. usually started on day 1 or 2 and pursued an intermit-
tent course during the infusion. It was easily controlled with stan-
dard antimetics. Mild diarrhoea occurred in seven patients and did
not appear to be temporally related to treatment. Half of the
patients had mild anorexia and/or fatigue which lasted for approx-
imately 2-3 days after the infusion. Alopecia. observed in 14
patients. occurred most frequently in patients who received three
or more courses at doses > 1.5 mg m-' day-l. Twenty per cent of
patients complained of headache while receiving the infusion. In
one patient. the infusion was discontinued on the third course as
she developed sensitivity to the drug (cutaneous rash, respiratory
difficulty. eosinophilia). These symptoms first appeared about 10
days after the initial infusion and became progressively more
severe with subsequent cycles. The patient s metastatic colorectal
cancer was stable through this period. Two patients presented with
a new diagnosis of a bleeding duodenal ulcer and oesophageal
varices. shortly after entrv into the trial.
Five patients treated at doses < 1.0 mg m-' day-1 had the
GI147211 infusions administered through peripheral veins. All of
these patients developed phlebitis at the site of venepuncture.
frequently requiring a change of the i.v. cannula at 24-48 h.
Phlebitis recovered in 7-24 days without apparent effect of the
applied local treatment. One patient had extravasation of drug in
the left forearm: this did not produce necrosis and was successfully
managed with local steroids and ice packs. The other 39 patients
were treated through central venous catheters. Five developed
associated infections requiring iv. antibiotics. The only toxic
a
A
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A
A
0.0 0.5 1.0 1.5
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Figure 4 Relationship between the percentage of reduction in neutrophils
(A) and platelets (B) vs the lactose Css. The curves represent the fit of the
data as described in the text
death in this study occurred in a non-neutropenic patient who
developed staphylococcal septicaemia in association with a
Hickman line infection. Three patients had their central vein
devices removed, including one w-ho developed a subclavian
venous thrombosis.
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PharmacokiWnetics
All 44 patients had blood sampling performed during the first
course ofGI147211. Derived lactone pharmacokinetic parameters
are shown in Table 4. There were nosignificant differences in drug
elimination between the two sites. Steady-state G1147211 blood
concentrations were reached in most patients between 14 and 26 h
into the 72-h infusion. Linear regression analysis revealed that the
GI147211 lactone Css increased with dose over the range
0.25-1.24 ng ml-' (r = 0.58. P < 0.05) (Figure 2). After the end of
infusion. the plasma lactone elimination was monoexponential
with a mean half-life of 7.5 h. Mean clearance values tended to
increase with dose (r'=0.31: P<0.05) and ranged from 776 to
1554 ml min-1 m-' (average 1074ml min-' m-2) over the dose
range studied (Figure 3).
Total GI14721 1 blood concentrations (lactone plus carboxylate)
were approximately four times greater than lactone concentrations.
The variability oftotal drug was greater than that ofthe lactone (the
activemoiety). Tenninal half-life oftotal GI14721 1 waslongerthan
that ofthe lactone: the harmonic mean value was 20.1 ± 34.5 h. The
clearance of the carboxylate averaged 300 ± 111 ml min-I m ' and
also showed a trend to increase with dose. Examination of indi-
vidual curves indicates that the 'steady-state' concentrations tend to
creep up slowly. consistent with the long half-life. These increases
in concentration are. however. minor.
Total G1147211 urine concentrations are available from 15
subjects. The mean fraction of drug excreted unchanged in the
urine (fe) was 0.114 ± 0.041 and the renal clearance averaged
164± 61 ml min- across the doses measured.
Pharnacodynamics
The CSS of the GI147211 lactone correlated with the decrease in
neutrophil and platelet counts using the sigmoid E model
(Figure 4A and B). While variability was high. a steep concentra-
tion-response curve was observed between 0.5 and 1.5 ng ml-l.
Based on this model. neutrophils were more sensitive than
platelets to G1147211 toxicity. The half-maximal concentration
was 0.75 ng ml-1 for the fonner and 1.4 ng ml-1 for the latter.
Anti-tumouractivity
Three partial responses lasting 8. 30 and 34+ weeks were
observed. One patient with breast cancer. who had received two
previous chemotherapy regimens (CMF and epirubicin) as well as
twopriorregimens ofhormonal therapy. experienced shrinkage of
cutaneous and lymph node disease. A patient with ovarian cancer
who had been treated with two platinum-based regimens experi-
enced a substantial decrease in CA125 and had control of ascites.
A patient with colorectal cancer metastatic to the liver, previously
treated with 5-fluorouracil and leucovorin, also had a partial
response. Two additional patients, one with colorectal cancer and
the other with hepatoma, had decreases in hepatic lesions of44%
and 36% respectively. All of these patients were treated at doses
> 1.5 mg m-2 day-'. with the exception of the patient with ovarian
carcinoma. who received 0.5 mg m-'day-'.
DISCUSSION
Treatment with GI147211 administered as a 72-h continuous infu-
sion in adults with malignant solid tumours was well tolerated on
an outpatient basis. As in studies of G1147211 given daily for 5
days, myelosuppression was the dose-limiting toxicity (Eckardt et
al. 1995). In the current trial, bone marrow toxicity appeared at all
dose levels and involved all haematopoietic lineages in a dose-
dependent manner. The degree ofplatelet toxicity was somewhat
more pronounced than that observed on a similar schedule with
topotecan (Burris et al. 1994). though more protracted infusions of
that drug result in comparable effects on bothlineages (Hochster et
al. 1994). The extent of prior therapy has also been a determinant
of bone marrow toxicity in the 5-day study of GI147211 and in
phase I trials of other topoisomerase I inhibitors (Grochow et al.
1992: Saltz et al. 1993; Haas et al. 1994: Eckardt et al, 1995:
Rubin et al. 1995). Both neutropenia and thromobocytopenia were
dose limiting in this study and both appeared to be related to the
extent ofprevious treatment. although the patient numbers in each
population did not allow forrigorous statistical analysis. Inheavily
pretreated patients. grade HI or IV toxicity was observed in all
patients treated at or above 1.5 mg m-2 day-'. Thus. the recom-
mended dose for phase H trials for previously treated patients is
1.2 mg m-2 day-' Among untreated and minimally pretreated
patients. the MTD was 2.0 mg m- day-'. At this dose. three of ten
patients developed grade IV neutropenia and fourgrade IH throm-
bocytopenia. All of these episodes were uncomplicated and were
of short duration (less than 5 days). apart from one case of
neutropenic fever. Therefore. an appropriate phase II dose would
be 1.75 mg m- day-'.
While the ability ofthe bone marrow to recover from GI147211
is an important factor. it may be observed from Table 2 that prior
treatment alone is insufficient to account forthe wide variability in
toxicity at a particular dose level (see, for example. the 2 mg m-'
day-' dose level). Nor do differences in drug exposure explain the
variability: as may be observed in Figure 4. a broad range oftoxi-
city outlines the characteristic sigmoidal curve. The steep concen-
tration-response curve is characteristic of this class of drug
(Grochow et al. 1992: Haas et al. 1994) and emphasizes the need
to understand the pharmacodynamic basis of drug effect. In vitro
studies of cell lines with varying topoisomerase I content suggest
that the expression of topoisomerase I may be a detenrninant of
camptothecin effect: the higher the topoisomerase I expression the
more sensitive the cell line to camptothecin-induced cytotoxicity
(Pommier et al. 1994). However. Pommier et al (1994) have
shown that topoisomerase I activity alone does not explain varying
sensitivity. In peripheral mononuclear cells from patients under-
going treatment with the topoisomerase I inhibitor topotecan. the
opposite relationship has been found: those expressing lower
topoisomerase I levels had more myelotoxicity (Khater et al.
1995). Clearly,a simple explanation for the variable toxicity is not
yet evident and additional pharmacodynamic studies are needed.
The modest incidence of non-haematological toxicity makes
GI14721 1 an excellent candidate forcombination with other drugs
orradiation therapy. Mild and easily preventable emesis and short-
lasting fatigue were the main complaints. In contrast to irinotecan.
G1147211 does not induce diarrhoea (Slichenmyer et al. 1993;
Potmesil. 1994: Abigerges et al. 1995). This may relate to the fact
that G1147211 is the active compound. while irinotecan is a pro-
drug which is converted to SN-38. the active metabolite. An
important site of this conversion appears to be the intestinal
mucosa. in which high levels of SN-38 may be formed locally.
with attendant mucosal damage (Gupta et al. 1994). The lack of
gastrointestinal toxicity of G1147211 doubtless accounted for the
infrequent finding of sepsis. even in the face of profound
neutropenia. Also remarkable is the absence of mucositis in the
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present study. Only one episode of grade IH stomatitis was seen.
and this occurred at 2.5 mg m-2 day-'. concomitantly with neutro-
penic fever. By contrast. mucositis was dose limiting in a 5-day
infusion phase I study of topotecan in leukaemic patients
(Kantarjian et al. 1993). The absence of urothelial toxicity is
similar to topotecan and is probably due to improved water solu-
bility (Emerson et al. 1995). The propensity ofGI147211 to induce
phlebitis at venepuncture sites with infusion times ofless than 24 h
makes the use ofcentral vein catheters aprerequisite forprotracted
administration schedules.
Anti-tumour activity was documented in five patients with
colon. ovary and breast cancers and hepatoma. These three partial
and two minor responses are particularly noteworthy as they
occurred in patients who had been previously treated with conven-
tional chemotherapy. This. coupled with the significant antiprolif-
erative activity ofGI147211 in preclinical models in breast. colon
and ovarian tumours (Emerson et al. 1995). and the anti-tumour
activity seen with the daily x 5-day regimen.justifies furtherphase
II evaluation GI14721 1. Except for the partial response in the
patient with ovarian cancer observed at 0.5 mg m-2 day-'. all other
tumour regressions appeared at higher dose levels (1.5-2.0 mg in-
day-'). suggesting a dose-response relationship. This high rate of
response was also identified in another GI14721 1 phase I trial and
these data suggest that the drug may have useful activity when
used in a population with less advanced disease.
Pharmacokinetic studies showed that Css was related to dose but
there was a two- to threefold variation in Css with dose level. Css at
doses 2 1.2 mg m-2 day-' were above 1 ng mF' which are poten-
tially cytotoxic (e.g. 50% growth inhibition concentration for the
melanoma cell line Lox was 0.592 ng ml-') (Emerson et al. 1995).
The Css oftopotecan lactone at MTD of 1.6 mg m-2 day-' adminis-
tered as a continuous infusion for 3 days every 3 weeks was
5.5 ng ml-l (Burris et al. 1994). These differences in drug levels at
doses that produce similar degrees of myelosuppression may be
accounted for by topotecan being measured from plasma and
G1147211 from whole blood. and the observation that the latter
compound is 2-5 times more active in in vitro models
(Slichenmyer et al. 1993: Emerson et al. 1995). It remains to be
seen ifthis enhanced potency ofGI14721 1 will translate to a selec-
tive advantage in clinical trials.
The terminal half-life (7.5 h) in the present study was higher
than that observed after 30 min infusions. possibly reflecting the
absence of tissue distribution which has already occurred during
the 72-h infusion period. Better characterization ofthe elimination
of the carboxylate would be achieved with later sampling points.
From these data. the slower clearance of the carboxylate form
(mean terminal half-life 20 h) may also provide a source ofcontin-
uing formation of lactone during the elimination phase. Although
greater interpatient variability wasobserved, the average clearance
increased with increasing dose. particularly at doses > 1.0 mg m-'
day-'. These data do not support a definitive conclusion. but rate-
limited elimination or binding processes may be operating at
higher doses. As the major route ofmetabolism ofthe lactone is its
conversion to the open ring acid form. it is unlikely that the
compound induces its own metabolism. In this study. approxi-
mately 11% of total GI147211 was recovered unaltered in urine.
confirming animal data that biliary and/or intestinal excretion are
the main routes ofelimination for this drug.
In summary. myelosuppression is the DLT of GI147211 as a
72-h infusion every 3 weeks. Haematological toxicity was dose-
related. non-cumulative. reversible and dependent on the extent of
prior chemotherapy. Central venous catheters are required as
prolonged infusions induce phlebitis. At the recommended doses
for phase II trials (1.75 mg m-2 day-' and 1.2 mg m-2 day-' for
untreated/minimally treated andheavily pretreated patients respec-
tively). the schedule is well tolerated in an outpatient basis with
minimal non-haematological toxicity and promising evidence of
anti-tumour activity. The anti-tumour activity documented in this
trial supports a broad phase II evaluation of this drug. which is
now in progress using the five daily dose schedule. In attempting
to optimize the therapeutic efficacy of GI1472 11. the duration of
tumour exposure to the drug may be increased by prolonging the
infusion time or by oral administration. For this reason. phase I
trials testing 14- and 21-day infusions every 4-5 weeks and a
bioavailability study of an oral formulation ofthe compound have
been started.
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